UNSPSC 51292004: Citalopram

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C20H21FN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0DHU5B8D6V, chemically known as 1,3-dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile but generally known as citalopram, which bears US NIH Compound Identifier 2771. European Medicines Agency schedules Citalopram in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07485MIG.

UNSPSC 51292004 Citalopram is a Commodity code, but the recent state and local procurement activity tagged under it does not reflect pharmaceutical inventory of this specific antidepressant. Seminole County, Florida's IFB60459723LAS, posted June 30, 2026 and due July 26, 2023, solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually—opioid-reversal medication and drug disposal equipment for community health initiatives, not citalopram. The mismatch suggests either a tagging error in the source data or that this code carries misclassified procurement activity. State and local procurement offices occasionally tag health and safety supplies under broad pharmaceutical codes when more specific taxonomy codes are unavailable or unknown to the issuing office.

Seminole County Community Health Building in Sanford, Florida represents the sole recent opportunity visible under this code. The IFB requires quarterly deliveries, electronic bid submission, drug-free workplace certification, E-Verify compliance, and fixed-fee pricing; vendors must carry workers' compensation, commercial general liability, and professional liability insurance. The contract term is two years with an optional one-year renewal, includes a three-month probationary termination provision, and may draw FEMA funding with associated federal compliance obligations. Because the opportunity as described does not align with citalopram distribution, pursuit depends on whether your firm supplies naloxone and drug deactivation systems to county health agencies—not on whether you distribute this specific antidepressant.